logo-top-r-w
  • HOME
  • ABOUT MORSE
    • The Team
    • Strategic Partners
      • Lorraine Boyle
      • Dominika Dabrowski
      • Stephen Filbey
      • Brent Korte
    • Careers
  • SERVICES
    • Our Services
    • Strategic Advice
      • MORSE pCPA Assessment
      • MORSE HTA Strategic Advice
    • Analyses
    • Advisory Boards
      • MORSE Advisory Panel (MAP)
    • Training
      • RWE/Innovative Agreements
      • Private Payer
      • Negotiation Simulation
      • Reimbursement Training
    • Reports
      • Canadian Reimbursement and Forecasting Timelines Report (CRaFT)
      • Drugs for Rare Diseases Sub-Report
      • Oncology and Biosimilar Sub-Report
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
  • LINKS
  • CONTACT US
logo-top-c-r
logo-top-r-w
  • HOME
  • ABOUT MORSE
    • The Team
    • Strategic Partners
      • Lorraine Boyle
      • Dominika Dabrowski
      • Stephen Filbey
      • Brent Korte
    • Careers
  • SERVICES
    • Our Services
    • Strategic Advice
      • MORSE pCPA Assessment
      • MORSE HTA Strategic Advice
    • Analyses
    • Advisory Boards
      • MORSE Advisory Panel (MAP)
    • Training
      • RWE/Innovative Agreements
      • Private Payer
      • Negotiation Simulation
      • Reimbursement Training
    • Reports
      • Canadian Reimbursement and Forecasting Timelines Report (CRaFT)
      • Drugs for Rare Diseases Sub-Report
      • Oncology and Biosimilar Sub-Report
  • NEWS
    • MORSE Signals
    • MORSE Wire
    • Publications
    • What’s New
  • EVENTS
  • LINKS
  • CONTACT US

No Files Completed or Closed by the pCPA – May 2020

June 23, 2020
-
Market Access News
-
Posted by MORSE - 3 min read.

pan-Canadian Pharmaceutical Alliance (pCPA): May 2020 Trends and Insights

 

May Highlights:

  • 8 products completed CADTH review
  • 5 products initiated pCPA negotiations
  • 0 negotiations were completed with an LOI
  • 0 negotiations were closed without an LOI
  • 1 file was closed without negotiation

There was an evident slow down in May as the pCPA continues to adjust to the evolving COVID-19 situation.  No negotiations were completed or closed for the first time in over three years and there are a growing number of files with CADTH recommendations that remain under pCPA consideration.
 

Files Under pCPA Consideration:

CADTH issued 8 new recommendations in May (24 files as of May 31).

PRODUCT INDICATION SPONSOR HTA REC’N* DATE TUC**
Crysvita
(burosumab)
X-Linked Hypophosphatemia Kyowa Kirin CDR May 27 4
Contrave
(naltrexone hydrochloride and bupropion hydrochloride)
Chronic weight management in adults Bausch Health CDR May 27 4
Kisqali
(ribociclib with fulvestrant)
Advanced or Metastatic Breast Cancer Novartis pCODR May 11 4
Beovu
(brolucizumab)
Age Related Macular Degeneration Novartis CDR May 21 10
Entyvio
(vedolizumab)
Ulcerative Colitis Takeda CDR May 19 12
Cabometyx
(cabozantinib)
Hepatocellular Carcinoma Ipsen pCODR May 7 24
Erleada
(apalutamide)
Metastatic Castration-Sensitive Prostate Cancer Janssen pCODR May 7 24
Nubeqa
(darolutamide)
Non-Metastatic Castration Resistant Prostate Cancer Bayer pCODR May 7 24

* REC’N DATE = Date of CDEC Final Recommendation (CDR), Date Notification to Implement Issued (pCODR)
** TUC = Time Under Consideration in calendar days to end of month or initiation date.

 

 

Signals Decoded:
 
The total number of files under consideration rose to 24 in May, which is the highest count in over a year. In addition, these files have been under consideration for an average of 2 months (range: 0-7 months), the first time since December 2018 that the month-end average time under consideration was ≥ 2 months. While both the volume of files and average time under consideration metrics are increasing, on average, the pCPA is still initiating negotiations within its target timeline of 40 business days.

 

Negotiation Initiation:

The pCPA initiated 5 new negotiations in May (25 active negotiations as of May 31)

PRODUCT INDICATION SPONSOR CATEGORY INITIATE DATE TTI*
Allerject
(epinephrine)
Emergency treatment of severe acute allergic reactions (anaphylaxis) Kaleo Other May 22 N/A
Avsola
(infliximab)
Ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn’s Disease & Ulcerative Colitis Amgen Biosimilar May 15 N/A
Kisqali
(ribociclib with fulvestrant)
Advanced or Metastatic Breast Cancer Novartis pCODR May 11 4
Keytruda
(pembrolizumab)
Renal Cell Carcinoma Merck pCODR May 11 21
Kadcyla
(trastuzumab emtansine)
Early Breast Cancer Hoffmann-La Roche pCODR May 21 105

* TTI = Time to Initiate in calendar days

 

 

Signals Decoded:
 
Joining the 4 biosimilar negotiations initiated in April, the latest biosimilar version of infliximab was added to the Active Negotiation list in May. The initiation of 3 oncology negotiations is perhaps an early indicator that some negotiating capacity has returned to the oncology table, although it is worth noting that all 3 are new indications for products which have an existing LOI.

 

Completed/Closed Negotiations:

The pCPA neither completed a negotiation with a Letter of Intent (LOI), nor closed a negotiation without an agreement in May 2020.

 

Signals Decoded:
 
April’s significant activity (11 completions + 2 closures) resulted in somewhat of a “re-set” of the active negotiation volume and average duration metrics. Although the total number of files under pCPA management (49) is at its highest level in 7 months, new negotiations are still being initiated and the volume of active files is well below historical levels. As several of the files concluded in April had been active for extended periods, as of May 31st, the 25 active files have been in this process phase (range 0-18 months) for an average of 3.96 months – the shortest month-end average negotiation duration measure on record.

 

 

Signals Decoded:
 
The files under consideration (Pomalyst and Idhifa) and in active negotiation (Kanuma) for an extended duration remain relatively low.

 

Not Negotiated:

The pCPA declined negotiations on 1 file in May 2020.

PRODUCT INDICATION SPONSOR DECLINE DATE TTD*
Rydapt
(midostaurin)
Systemic Mastocytosis Novartis May 25 35

* TTD = Time to Decline in calendar days

 

Signals Decoded:
 
Rydapt received a “do not reimburse” recommendation from CADTH and was declined without negotiations in May.

 

To receive updates similar to this one please be sure to sign up for MORSE Signals, our free e-mail newsletter service.

 

 

Share
Tags
Biosimilars
CADTH
CDEC
Oncology
Pan Canadian Pharmaceutical Alliance
pCPA
pCPAO
pERC
← PREVIOUS POST
CADTH Pharmaceutical Reviews Update, Issue 16
NEXT POST →
Early Insights into pCPA Prioritization

Contact Us
MORSE Consulting Inc.
Toronto | Ottawa, Canada
+1-647-717-3179 (Toronto)
+1-613-864-8645 (Ottawa)
info@morseconsulting.ca
Social
Connect & Follow:

New Report

Newsletter – MORSE Signals
Sign up for our free e-mail newsletter service and receive timely and relevant updates related to the emerging developments in the Canadian pharmaceutical reimbursement landscape.

Sign Up
MORSE Consulting Inc. | Deciphering Canadian pharmaceutical market access signals to create reimbursement success.
© 2023 MORSE Consulting Inc. All rights reserved. | Site by Directica Media
No Files Completed or Closed by the pCPA - May 2020